Clinical Trial Update: Icotinib as the Adjunctive Treatment After Surgery in Stage I-IIIB Lung Adenocarcinoma Patients With EGFR Gene Mutation [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial evaluating icotinib as adjuvant therapy after surgery for EGFR-mutant stage I-IIIB non-small cell lung cancer (lung adenocarcinoma); cu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• icotinib (icotinib)

Snippet

Sponsor: Chinese PLA General Hospital | Conditions: Neoplasms, Therapy-Associated | Phase 4 | Status: UNKNOWN